Allogene Therapeutics
Preeti Hadavale is a skilled scientist with extensive experience in process development within the biotechnology field. Currently serving as a Scientist in Process Development at Allogene Therapeutics since October 2021, Preeti previously worked as a Senior Research Associate and Research Associate at Kite Pharma from June 2018 to October 2021, focusing on the production of lentiviral vectors using various cell lines and bioreactor systems. Preeti also contributed to stem cell research at iXCells Biotechnologies as a Research Associate, handling routine stem cell culture and differentiation into neuronal lineages. Additionally, Preeti gained experience as a Research Intern at Cedars-Sinai, investigating the differentiation of iPSCs and ESCs into hepatic lineage cells. Preeti holds a Master’s Degree in Biotechnology and Bioinformatics with an emphasis in Stem Cell Technology and Laboratory Management from California State University Channel Islands and a Bachelor of Technology in Biotechnology from Dr. D. Y. Patil Vidyapeeth.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.